CANF Stock Analysis: Buy, Sell, or Hold?
CANF - Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares
$1.78
-0.05 (-2.73%)
▼
5d:
+1.14%
30d:
-17.97%
90d:
-43.49%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Apr 13, 2026
0d
Get Alerted When CANF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CANF shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CANF shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CANF is currently trading at $1.78, which is considered oversold relative to its 30-day fair value range of $1.90 to $2.23.
Technical Outlook: Technically, CANF is in a downtrend. The price is currently testing key support at $1.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CANF scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.00 (+349.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CANF is in a downtrend. The price is currently testing key support at $1.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CANF scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.00 (+349.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.90 -
$2.23
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 349.4% below Wall St target ($8.00)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.90 -
$2.23
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.75
Resistance Level
$2.02
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.96
Wall Street Target
$8.00
(+349.4%)
Share & Embed Analysis
Last updated: October 24, 2026 7:50 AM ET
Data refreshes hourly during market hours. Next update: 8:50 AM
Data refreshes hourly during market hours. Next update: 8:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CANF showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$106 | 50 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 58 HOLD |
